Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
NCT05982561 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2026-04-23
Summary
BCDx is a urine-based multi-omic assay for early cancer recurrence detection in patients with a history of bladder cancer. This prospective, blinded study evaluates its efficacy in detecting recurrent NMIBC, offering a noninvasive monitoring solution.
Conditions
Sponsors & Collaborators
-
Early is Good Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-07-26
- Primary Completion
- 2026-08-31
- Completion
- 2026-08-31
Countries
- United States
Study Locations
More Related Trials
-
Longitudinal Bladder Cancer Study for Tumour Recurrence
NCT05080998 ·Status: RECRUITING
-
The Cxbladder Rule-out of Recurrent Urothelial Carcinoma
NCT03673202 ·Status: UNKNOWN
-
Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer
NCT02969109 ·Status: COMPLETED
-
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
NCT05796375 ·Status: RECRUITING ·Phase: PHASE2
-
A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
NCT05508568 ·Status: UNKNOWN
-
Clinical Evaluation of the miR Sentinel BCa™ Test to Diagnose Bladder Cancer in Hematuria Patients
NCT04155359 ·Status: ACTIVE_NOT_RECRUITING
-
Bladder Cancer Patient-Reported Outcomes
NCT01090388 ·Status: COMPLETED
-
Follow-Up of Bladder Cancer Patients From the New England Study of Environment and Health
NCT00776178 ·Status: COMPLETED
-
Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma
NCT02647112 ·Status: COMPLETED ·Phase: NA
-
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
NCT01731652 ·Status: COMPLETED ·Phase: PHASE2
-
Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder
NCT02745301 ·Status: COMPLETED
-
A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)
NCT03664258 ·Status: COMPLETED
-
Xpert Bladder Monitor: a Non-Invasive Follow-Up Tool for Detecting Relapse in High Grade or High Risk Bladder Cancer
NCT06751667 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases
NCT06870253 ·Status: ACTIVE_NOT_RECRUITING
-
A Diagnostic for the Early Detection of Bladder Cancer
NCT05347342 ·Status: ACTIVE_NOT_RECRUITING
-
Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
NCT06126796 ·Status: COMPLETED
-
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
NCT03193541 ·Status: RECRUITING
-
Urine Cytology and Utility in Bladder Recurrence
NCT00971256 ·Status: COMPLETED
-
A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer
NCT03193515 ·Status: RECRUITING
-
Onco4D(TM) Biodynamic Chemotherapy Selection for Bladder Cancer Patients
NCT03739177 ·Status: UNKNOWN
-
Analysis of Urinary Methylation Patterns Via Liquid Biopsy as an Early Diagnosis Tool
NCT06878027 ·Status: RECRUITING
-
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
NCT05672615 ·Status: RECRUITING
-
Bladder Cancer Screening Trial
NCT05646485 ·Status: RECRUITING ·Phase: NA
-
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
NCT06331299 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
NCT07322263 ·Status: RECRUITING ·Phase: PHASE2